Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Adil Abdalla

Gastroenterology Flint, MI Medical Doctor

NPI 1245215292 CMS profile 101540

6240 Rashelle Dr Ste 204, Flint, MI 48507

Open in the dashboard

General payments

$8,570

435 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Adil Abdalla of Flint, MI is reported in the CMS Open Payments database as having received $8,570 across 435 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,361 69
2024 General $1,697 79
2023 General $1,485 70
2022 General $1,909 85
2021 General $1,307 87
2020 General $420 27
2019 General $392 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Adil Abdalla
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Adil Abdalla were reported at $1,361. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Adil Abdalla Gastroenterology median Middle half National median
2019 $392 $417 $126–$1,100 $163
2020 $420 $224 $74–$624 $114
2021 $1,307 $352 $106–$1,054 $132
2022 $1,909 $448 $129–$1,270 $149
2023 $1,485 $533 $150–$1,390 $160
2024 $1,697 $605 $160–$1,606 $164
2025 $1,361 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $3,356 186 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $712 40 payments
  3. Gilead Sciences, Inc. $709 48 payments
  4. Janssen Biotech, Inc. $395 15 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $372 21 payments
  6. Alnylam Pharmaceuticals Inc. $324 12 payments
  7. Regeneron Healthcare Solutions, Inc. $291 8 payments
  8. Genzyme Corporation $246 10 payments
  9. Intercept Pharmaceuticals, Inc. $239 15 payments
  10. Mallinckrodt Hospital Products Inc. $233 7 payments
  11. Other $1,693 73 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,421 430 payments
  2. Education $132 4 payments
  3. Debt forgiveness $17 1 payment
Products named General payments · program years 2019–2025
  1. RINVOQ $1,183 59 payments
  2. SKYRIZI Immunology $779 42 payments
  3. CREON $713 41 payments
  4. LINZESS $595 31 payments
  5. HUMIRA $564 29 payments
  6. ENTYVIO $407 24 payments
  7. STELARA $395 15 payments
  8. XIFAXAN $391 22 payments
  9. SKYRIZI Immunology $355 20 payments
  10. MAVYRET $346 30 payments
  11. Other $4,078 178 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

978

Median for Internal Medicine: 777

Drug cost

$24,487

Median for Internal Medicine: $73,373

Branded share of claims

37.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 14 $8,511
Pantoprazole Sodium Generic 323 $3,935
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 189 $3,607
Omeprazole Generic 201 $2,069
Dexlansoprazole Dr Dexlansoprazole Brand 13 $1,942
Peg-3350 And Electrolytes Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 109 $1,907
Peg 3350-Electrolyte Sodium Chloride/Nahco3/Kcl/Peg Brand 32 $891
Ursodiol Generic 11 $715
Spironolactone Generic 26 $265
Clarithromycin Generic 12 $256

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$4,650

Medicare's payments for the services billed

Medicare patients

38

Average age 72

Services billed

44

18 women, 20 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Diabetes 47%
Ischemic heart disease 37%
Heart failure 34%
COPD 34%
Chronic kidney disease 32%
Atrial fibrillation 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $125
  • Regeneron Healthcare Solutions, Inc. $45
$170 — —
STELARA
  • Janssen Biotech, Inc. $165
$165 — —
RINVOQ
  • AbbVie, Inc. $165
$165 — —
SKYRIZI
  • AbbVie, Inc. $156
$156 — —
LINZESS
  • AbbVie, Inc. $119
  • Ironwood Pharmaceuticals, Inc $17
$136 14 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

435 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record